BioSpace News Archive

EMPA-KIDNEY Phase III clinical trial met its primary endpoint by demonstrating a significant kidney and cardiovascular benefit for people living with chronic kidney disease (CKD).

Mesa Laboratories, Inc. announced that Shiraz Ladiwala has been appointed to serve as the Lead Independent Director of its Board of Directors, effective November 3, 2022.

Fate Therapeutics, Inc. announced that the Company will present at the following upcoming investor conferences.

Apellis Pharmaceuticals, Inc. announced that the company approved the grant of equity awards to 7 new employees with a grant date of November 1, 2022, as equity inducement awards outside of the company’s 2017 Stock Incentive Plan and material to the employees’ acceptance of employment with the company.

Amgen (NASDAQ:AMGN) will present at the Credit Suisse 31st Annual Global Healthcare Conference at 3:50 p.m. ET on Wednesday, November 9, 2022. David M. Reese, M.D., executive vice president of Research and Development and Peter H. Griffith, executive vice president and chief financial officer at Amgen will present at the conference.

Atara Biotherapeutics, Inc., a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, reported the grant of 7,200 restricted stock units of Atara’s common stock to two newly hired employees.

Insulet Corporation, announced on October 17, 2022, a Medical Device Correction for all Omnipod DASH® Personal Diabetes Managers distributed globally.

AbCellera announced that executives from the Company will present at the following investor conferences.

Bioretec Ltd, a pioneer in biodegradable orthopedic implants, expects the European marketing authorization for the RemeOs™ trauma screw to be delayed from the original estimate of 2022.

Oxurion NV announced that, pursuant to Belgian Transparency legislation1 it has received transparency notification following the issuance of new shares pursuant to the Capital Commitment entered into with Negma Group.